Literature DB >> 3202164

Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells.

H J Motulsky1, M C Michel.   

Abstract

Neuropeptide Y (NPY), a peptide often coreleased with catecholamines, appears to be an important component of the sympathetic nervous system, but little is known about the molecular basis of its action. We introduce here human erythroleukemia (HEL) cells as a new model system for studies of NPY action. NPY inhibited adenosine 3,5'-cyclic monophosphate (cAMP) accumulation in HEL cells with a 50% effective concentration (EC50) of 3 nM. Additionally NPY increased intracellular Ca2+, as assessed by fura-2 fluorescence, with a similar EC50. Pretreatment with pertussis toxin blocked both responses, suggesting the involvement of one or more G proteins. Chelating extracellular Ca2+ with EGTA did not reduce the Ca2+ signal, demonstrating mobilization from intracellular stores rather than influx. Experiments with various agents demonstrated that the Ca2+ mobilization was not secondary to lowering of cAMP levels, formation of arachidonic acid products, or Na+-H+ exchange. Ca2+ mobilization also did not appear to be associated with inositol phosphate generation. In conclusion, we demonstrate for the first time that NPY, in addition to inhibiting adenylate cyclase, also can elevate intracellular Ca2+. HEL cells should prove useful in further studies of the molecular basis of NPY action.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3202164     DOI: 10.1152/ajpendo.1988.255.6.E880

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  24 in total

1.  Pancreatic beta cells require NeuroD to achieve and maintain functional maturity.

Authors:  Chunyan Gu; Gretchen H Stein; Ning Pan; Sandra Goebbels; Hanna Hörnberg; Klaus-Armin Nave; Pedro Herrera; Peter White; Klaus H Kaestner; Lori Sussel; Jacqueline E Lee
Journal:  Cell Metab       Date:  2010-04-07       Impact factor: 27.287

2.  Neuropeptides in hypertension: role of neuropeptide Y and calcitonin gene related peptide.

Authors:  T C Westfall; S P Han; M Knuepfer; J Martin; X L Chen; K del Valle; A Ciarleglio; L Naes
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

Review 3.  Deconstructing pancreas developmental biology.

Authors:  Cecil M Benitez; William R Goodyer; Seung K Kim
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-06-01       Impact factor: 10.005

4.  Sphingosine kinase-mediated Ca2+ signalling by G-protein-coupled receptors.

Authors:  D Meyer zu Heringdorf; H Lass; R Alemany; K T Laser; E Neumann; C Zhang; M Schmidt; U Rauen; K H Jakobs; C J van Koppen
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

Review 5.  New targets to treat obesity and the metabolic syndrome.

Authors:  Kathleen A Martin; Mitra V Mani; Arya Mani
Journal:  Eur J Pharmacol       Date:  2015-05-19       Impact factor: 4.432

6.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

7.  Differential calcium signalling by m2 and m3 muscarinic acetylcholine receptors in a single cell type.

Authors:  M Schmidt; C Bienek; C J van Koppen; M C Michel; K H Jakobs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-11       Impact factor: 3.000

8.  G-protein coupling and signalling of Y1-like neuropeptide Y receptors in SK-N-MC cells.

Authors:  F Feth; W Rascher; M C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

Review 9.  The NPY system and its neural and neuroendocrine regulation of bone.

Authors:  Ee Cheng Khor; Paul Baldock
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

10.  Cyclic AMP counteracts mitogen-induced inositol phosphate generation and increases in intracellular Ca2+ concentrations in human lymphocytes.

Authors:  L J van Tits; M C Michel; H J Motulsky; A S Maisel; O E Brodde
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.